MedTrace Logo

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01665794 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-12-22

No results posted yet for this study

Summary

The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete.

This study will also investigate the effects of adding daratumumab to the combination of carfilzomib, pomalidomide and dexamethasone.

Conditions

Interventions

DRUG

Pomalidomide

Pomalidomide taken orally at assigned dose.

DRUG

Carfilzomib

Carfilzomib given by intravenous (IV) infusion at assigned dose.

DRUG

dexamethasone

Dexamethasone taken orally of given by IV infusion.

DRUG

Daratumumab

Daratumumab given by intravenous (IV) infusion at assigned dose.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Multiple Myeloma Research Foundation

    collaborator OTHER

  • University of Chicago

    lead OTHER

Principal Investigators

  • Andrzej Jakubowiak · University of Chicago Comprehensive Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-13
Primary Completion
2025-11-14
Completion
2025-11-14
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01665794 on ClinicalTrials.gov